Chargement en cours...
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
The use of targeted therapeutics directed against BRAF(V600)-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge. By far, the most common clinical resistance mechanism involves reactivation of the MAPK (R...
Enregistré dans:
| Publié dans: | Cancer Res |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4300142/ https://ncbi.nlm.nih.gov/pubmed/25320010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2073 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|